VIOLETTE: what clinicians are saying
ceralasertib plus olaparib; adavosertib plus olaparib in metastatic triple-negative breast cancer · NCT03330847 ↗ · Phase 2 · AstraZeneca
A medical oncologist expresses disappointment with VIOLETTE, relaying no significant progression-free survival gain with ceralasertib–olaparib. An organization sees possible activity beyond HRR mutations but considers the clinical significance limited. Another medical oncologist links adavosertib–olaparib’s discontinuation to toxicity. A speaker suggests functional HRD or replication-stress biomarkers might refine selection; their predictive value is not established. These views establish neither routine-care preferences nor broader clinical agreement.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 24 verified statements
4 findings, and what sits behind each
01. VIOLETTE responses: a speaker highlights no significant PFS gain across strata
1 of the report's 2 cited clinicians · 12 statements from 2 speakers in 5 sources · 9 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Progression-free Survival Per Stratum (BICR), Population and setting, Secondary endpoints, The comparison, Safety and tolerability.
02. Adavosertib–olaparib: a clinician highlights toxicity behind the arm’s closure
1 of the report's 2 cited clinicians · 7 statements from 2 speakers in 5 sources · 6 passages
Limitations recorded: 2.
Draws on: The comparison, Safety and tolerability, Design and conduct.
03. Non-HRR-mutated TNBC: a speaker asks if biomarkers could predict ATR–PARP benefit
1 of the report's 2 cited clinicians · 6 statements from 3 speakers in 4 sources · 8 passages
Limitations recorded: 2.
Draws on: Population and setting, Primary endpoint: Progression-free Survival Per Stratum (BICR), The comparison, Safety and tolerability.
04. VIOLETTE in 2017: a speaker looks forward to starting the trial
No named clinician · accounts and unnamed speakers · 2 statements from 2 speakers in 2 sources · 2 passages
Limitations recorded: 2.
Draws on: Design and conduct.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
1 of the report's 2 cited clinicians
VIOLETTE responses: a speaker highlights no significant PFS gain across strata
12 statements from 2 speakers in 5 sources
1 of the 2 named speakers in this finding holds this view
- 12
- statements
- 9
- passages
- 5
- sources
- 2
- speakers
What the statements areViews 4Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 7Statement-to-passage links (a passage can back several statements)Supporting a statement 14Giving context 0Recorded with the findingLimitations: 3
4 posts and articles · 1 publication
Draws on: Primary endpoint: Progression-free Survival Per Stratum (BICR), Population and setting, Secondary endpoints, The comparison, Safety and tolerability.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (6)
BICR, blinded independent central review; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.
The full VIOLETTE report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
In VIOLETTE’s second-/third-line, PARP inhibitor-naïve metastatic TNBC setting, what do clinicians need to see in PFS versus olaparib alone to consider response activity with ceralasertib plus olaparib clinically relevant, particularly in non-HRR-mutated disease?
From finding F1 (12 statements from 2 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 19commentary sources screened
- 7sources cited by verified statements
- 6named in screened sources
- 6speakers cited in the report
- 5cited speakers with a verified identity
2 cited clinicians, speakers with a confirmed clinical role, of them 2 physicians. By role and specialty:
- 2 physician, Medical oncology
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 24verified statements, each linked to its source
- 4of them from speakers with a confirmed clinical role
- 4findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 24 | Paid |
| Who said each statement: the cited speakers | 6 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 2 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 7 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
8 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-free Survival Per Stratum (BICR) | 7 | 3 |
| Primary endpoint: Progression-free Survival Per Stratum (Sensitivity Analysis)no commentary found | 0 | 0 |
| Secondary endpoints | 5 | 2 |
| Population and setting | 9 | 3 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 10 | 4 |
| Safety and tolerability | 5 | 4 |
| Design and conduct | 5 | 5 |
| Questions about biomarker refinement and responder biology | 4 | 2 |
| Early ATR rationale and trial-launch expectations | 2 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
24 verified statements from 7 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 18 statements · 75% | ||||
| X threads | 18 | 6 | 18 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 6 statements · 25%cited for context, not screened | ||||
| Publications | 6 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 9 / quarter
- Screened window
- Dec 7, 2017 → Oct 23, 2026
- Cited window
- Dec 7, 2017 → Oct 7, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).
- Registry
- NCT03330847
- Study IDs
- D5336C00001 · 2017-002361-22
- Sponsor
- AstraZeneca
- Design
- Phase 2 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 273 actual
- Registered
- 2017-11-06
- Start
- 2018-03-07 actual
- Primary completion
- 2020-11-13 actual
- Primary endpoints
- Progression-free Survival Per Stratum (BICR)
- Progression-free Survival Per Stratum (Sensitivity Analysis)
- Interventions
- 3 registered
More on: Breast cancer, ceralasertib, adavosertib
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on planned olaparib combination comparisons and HR-pathway stratification in metastatic triple-negative breast cancer.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 42 sources about other trials or topics are not included; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- Relevant discussions that do not name VIOLETTE or use different spellings may be missing; the sources reviewed for this edition do not represent all public HCP commentary.
Show all 9 known gaps +Fewer −
- Publication-linked summaries, reposts and credited relays should not be counted as independent HCP evaluations or evidence of consensus.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- ClinicalTrials.gov first posted results for the trial on 22 March 2022.
- Exact regulatory-label information for the three study regimens was not available; this report does not assess labeled indications or dosing.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. VIOLETTE (NCT03330847): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/violette-nct03330847
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "VIOLETTE" (NCT03330847), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "violette-nct03330847". If you cannot make requests, read https://www.erudio.com/reports/violette-nct03330847.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT03330847", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT03330847 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/violette-nct03330847.json
curl https://www.erudio.com/reports/violette-nct03330847.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "violette-nct03330847" })release 4737b1b26a08a1ca4647be9c3ade0740e7ade96387c7b158048bbdd6fc24ae17
Questions
How much does the VIOLETTE report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the VIOLETTE report cover?
24 statements from 7 sources (6 posts, 1 paper), 4 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the VIOLETTE report?
Its preview, yes: get_report_card({ "slug": "violette-nct03330847" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the VIOLETTE report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.